Compare JVA & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JVA | CLGN |
|---|---|---|
| Founded | 1971 | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Industrial Specialties |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.0M | 23.1M |
| IPO Year | 2005 | N/A |
| Metric | JVA | CLGN |
|---|---|---|
| Price | $3.67 | $1.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $11.50 |
| AVG Volume (30 Days) | ★ 35.5K | 27.1K |
| Earning Date | 01-30-2026 | 11-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 64.91 | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $89,748,681.00 | $2,475,000.00 |
| Revenue This Year | N/A | $1,617.28 |
| Revenue Next Year | N/A | $83.54 |
| P/E Ratio | $11.21 | ★ N/A |
| Revenue Growth | 17.92 | ★ 280.77 |
| 52 Week Low | $2.75 | $1.30 |
| 52 Week High | $9.93 | $4.98 |
| Indicator | JVA | CLGN |
|---|---|---|
| Relative Strength Index (RSI) | 49.02 | 34.38 |
| Support Level | $3.31 | $1.30 |
| Resistance Level | $3.74 | $1.93 |
| Average True Range (ATR) | 0.17 | 0.15 |
| MACD | 0.03 | -0.05 |
| Stochastic Oscillator | 80.77 | 28.52 |
Coffee Holding Co Inc is engaged in wholesale coffee operations, including manufacturing, roasting, packaging, marketing, and distributing roasted and blended coffees for privately labeled accounts and its brands, and it sells green coffee. The Company also manufactures and sells coffee roasters. Its products include wholesale green coffee, private-label coffee, and branded coffee. The company sells its coffee products throughout the United States, Canada, and certain Asian countries. The group's services are Custom Blending, Food Service Programs, and Private Label Services.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.